Review

Harnessing preclinical mouse models  
to inform human clinical cancer trials

David H. Gutmann,1 Kim Hunter-Schaedle,2 and Kevin M. Shannon3

1Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.  

2Children’s Tumor Foundation, New York, New York, USA. 3Department of Pediatrics, UCSF, San Francisco, California, USA.

The	urgent	need	for	better	cancer	treatments	has	stimulated	interest	in	employing	small-animal	models	to	evaluate	
potential	drug	therapies.	Robust	mouse	models	of	many	human	cancers	have	been	generated	using	sophisticated	
technologies	for	engineering	germ-line	mutations.	As	we	enter	into	an	age	of	targeted	therapeutics,	these	strains	
provide	novel	platforms	for	validating	new	anticancer	drugs,	assessing	therapeutic	index,	identifying	surrogate	
markers	of	tumor	progression,	and	defining	epigenetic	and	environmental	influences	on	tumorigenesis.

The availability of strains of genetically engineered mice (GEM) 
that develop a spectrum of cancers similar to those found in 
humans  offers  an  unprecedented  opportunity  to  efficiently 
evaluate the efficacy and therapeutic index of novel anticancer 
therapies in preclinical models in advance of human trials. While 
straightforward in principle, executing preclinical studies in mice 
that allow for meaningful and immediate application to the treat-
ment of human cancer is difficult. Moreover, the potential use of 
GEM cancer models to accelerate the process of bringing effective 
new treatments to patients is largely theoretical, as few examples 
exist in which mouse preclinical data has been successfully trans-
lated to clinical practice.

The current development process for anticancer drugs
Taking a drug from discovery to market is an arduous process 
that frequently takes longer than 15 years and costs more than 
$800 million. Most agents that are advanced into early-phase 
human clinical trials fail. Recent advances in the fields of cancer 
biology and high-throughput screening have identified numer-
ous potential molecular targets for drug discovery; however, 
most of the proteins and pathways deregulated in cancer cells 
also have essential roles in normal cells. It is therefore difficult to 
predict when a drug will prove tumor-selective. Moreover, devel-
oping new therapies against specific molecular abnormalities in 
well-defined subsets of cancers can be prohibitively expensive. 
The use of GEM cancer models as an initial “filter” to identify 
tumors and molecular targets that, when inhibited, will selec-
tively kill tumor cells is one potential strategy for streamlining 
the overall process of cancer drug development.

Preclinical mouse models of human cancer
Numerous small-animal models of human cancer have been gen-
erated. These include inbred strains that spontaneously develop 
cancer (1–4), rodents in which cancer is caused by intrauterine 
or postnatal exposure to chemical mutagens (5–9), and mice in 

Nonstandard	abbreviations	used: APL, acute promyelocytic leukemia; ATRA, 
all-trans-retinoic acid; Ftase, farnesyltransferase; FTI, farnesyltransferase inhibitor; 
GEM, genetically engineered mouse; MPNST, malignant peripheral nerve sheath 
tumor; MTD, maximally tolerated dose; NF1, neurofibromatosis 1; PK/PD, phar-
macokinetic and pharmacodynamic; PML, promyelocytic leukemia; RARA, retinoic 
acid receptor alpha.
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J. Clin. Invest. 116:847–852 (2006). doi:10.1172/JCI28271.

which tumors are produced by viral or bacterial infection (10–13). 
In addition, xenograft models that were generated by directly 
implanting cancer cell lines established from human tumors into 
mice have been widely used for drug discovery (14–17). The major 
limitations of these explant models are the requirement for an 
immunocompromised host and the inability of these models to 
fully recapitulate the complex relationship between the tumor and 
its microenvironment (e.g., angiogenesis). Most importantly, the 
ability of xenografts to accurately predict drug efficacy in human 
cancer patients has been disappointing (18).

GEM cancer models are becoming increasingly sophisticated 
in their ability to accurately mimic the histology and biological 
behavior of human cancers. Numerous tissue-specific GEM mod-
els have been developed that exhibit many biologic hallmarks of 
human cancer, including angiogenesis and stromal interactions, 
as well as similar histopathologic and genetic abnormalities (19). 
The major advantages of GEM models are that: (a) the initiating 
genetic event is known; (b) the mice are immunocompetent; and 
(c) the tumors develop spontaneously in their appropriate tis-
sue compartments. Moreover, GEM cancer models, which allow 
assessment of therapeutic efficacy on a uniform genetic back-
ground, are particularly useful for performing preclinical stud-
ies of rare cancers and for assessing synergy between therapeutic 
agents. They can also potentially provide the tools needed to learn 
more about the histologic and biochemical effects of specific 
agents prior to human testing.

While GEM models offer many advantages, the cancers typi-
cally arise from genetic events that are expressed simultaneously 
in many cells throughout an animal or in an entire tissue. By con-
trast, most human tumors are believed to arise from single cells or 
from a small population of mutant cells. To overcome this limita-
tion, strategies have been developed that allow mutant alleles to be 
expressed in small populations of cells in vivo (20, 21).

Opportunities to employ mouse models
The availability of robust GEM models facilitates a detailed analy-
sis of human cancer that cannot be easily accomplished by study-
ing primary human tumors (see Opportunities provided by employing 
GEM cancer models). First, the ability to more effectively treat human 
cancers requires a detailed understanding of molecular and cellular 
pathogenesis to identify specific molecular targets. Second, there 
is also a great need to define those individuals at greatest risk for 
developing cancer as well as those most likely to respond to any 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006 

847

review

given therapeutic regimen. These studies require large numbers 
of individuals and are often not possible for less common cancers. 
Last, the identification of surrogate markers of tumor formation 
and early response to therapy, which would have tremendous 
impact on current treatment strategies, is another unmet need.

Evaluation of standard human antitumor therapies. One of the often 
neglected uses of GEM cancer models is the validation of conven-
tional therapies employed for the treatment of cognate tumors 
in humans. For example, accurate GEM models of astrocytoma 
or pancreatic cancer should ideally respond to the same treat-
ments currently used to treat these cancers (i.e., temozolomide 
and gemcitibene, respectively). In addition, GEM models afford 
the opportunity to define the mechanism(s) underlying the anti-
tumor effects. Tumors from mice treated with anticancer thera-
pies can be analyzed to determine whether regression results from 
decreased cell growth, increased cell death, decreased tumor angio-
genesis, or necrosis. Failure to observe any effects on GEM tumors 
may reflect problems with bioavailability (e.g., inability to cross 
the blood-brain barrier), differences in the metabolic processing 
of drugs in rodents (e.g., pharmacokinetic and pharmacodynamic 
[PK/PD] issues), and/or genetic differences between mouse strains 
that dictate the response to therapy (e.g., modifier loci).

Experience with a mouse model of acute promyelocytic leuke-
mia (APL) suggests that GEM models respond to human cancer 
treatments and can be used to improve therapy. In APL, blasts 
are arrested at the promyelocytic stage of differentiation due to 
chromosomal translocations that fuse the retinoic acid receptor alpha 
(RARA) gene to a variety of partner genes including promyelocytic 
leukemia (PML) and promyelocytic leukemia zinc finger (PLZF). All-
trans-retinoic acid (ATRA) induces complete remissions in approxi-
mately 80% of patients with APL who have a PML-RARA transloca-
tion by relieving the differentiation block (22) but does not induce 
remission in those individuals with PLZF-RARA fusions (23). Simi-
larly, ATRA induces remissions in PML-RARA transgenic mice but 
is ineffective in a PLZF-RARA strain that also develops APL (24). In 
addition, mouse models of APL have been harnessed to test new 
therapeutic approaches such as arsenic trioxide (As2O3) and the 
potential synergy between ATRA and As2O3 (25, 26).

The role of specific cancer genes. GEM strains have been generated 
that model the inactivation of genes mutated in inherited cancer 
syndromes (e.g., neurofibromatosis 1 [NF1], NF2, APC), in sporadic 
cancers (e.g., KRAS, PML-RARA), and in both types of cancer (e.g., 
TP53) (27–46). GEM models based on these tumor suppressors 
and oncogenes provide unique opportunities to clearly define the 
causative role of each of these genetic changes in tumor forma-
tion and progression. This information is critical for the design of 
targeted (biologically based) therapies for individual cancers with 
these specific tumor-associated mutations.

Target validation. GEM cancer models can be used to determine 
whether the success or failure of a given therapy reflects the ability 
of the drug to reach the tumor and inhibit its target. An illustra-
tive example of how GEM cancer models can provide insights into 
mechanisms of drug activity comes from studies that evaluated 
the efficacy and putative biochemical targets of farnesyltransferase 
(FTase) inhibitors (FTIs). Ras processing is initiated by cytosolic 
prenyltransferases, which attach either a farnesyl or geranylgera-
nyl isoprenoid lipid to the thiol group of the cysteine. Geranyl-
geranyl transferase 1 (GGTase-1) and FTase catalyze the transfer 
of isoprenoid groups, which are donated by geranylgeranyl pyro-
phosphate and farnesyl pyrophosphate, respectively. FTIs were 
developed as cancer therapeutics based on their potential as Ras 
inhibitors in xenograft models. However, KRAS and NRAS are 
also good GGTase-1 substrates and are processed by this enzyme 
when FTase is inhibited. Preclinical studies of the efficacy of FTIs 
gave variable results in transgenic mouse models of breast cancer 
induced by expressing oncogenic HRAS or KRAS from the murine 
mammary tumor virus promoter (47–49) and in a model of myelo-
proliferative disease induced by inactivating the Nf1 tumor sup-
pressor (50), which encodes a GTPase-activating protein that nega-
tively regulates RAS signaling. Importantly, careful biochemical 
investigation of tumor tissues from these mouse models unequiv-
ocally showed no inhibition of KRAS or NRAS processing at the 
maximally tolerated dose (MTD) of FTI. Based on these data, it 
was concluded that any therapeutic effects of FTIs were due to 
“off-target” activities that were not related to the original goal of 
inhibiting hyperactive RAS.

Defining the discrete steps of tumorigenesis. GEM cancer models can be 
used to dissect the cellular and molecular changes associated with 
each stage of neoplasia, including tumor formation, tumor main-
tenance, and malignant progression. Studies focused on defining 
the events associated with tumor formation in multistep cancers 
are essentially chemoprevention investigations. Direct chemopre-
vention studies in people at risk for cancer are difficult, owing to 
the genetic heterogeneity in human populations and the difficul-
ties in accurately measuring exposure, which necessitate large and 
enormously expensive long-term studies. By contrast, experiments 
in GEM cancer models can be performed on a uniform genetic 
background in which environmental exposures are rigorously con-
trolled. GEM cancer models have been employed to establish causal 
relationships with environmental exposures (e.g., asbestos in meso-
thelioma, tobacco and lung cancer; diet in colon cancer)	(51–55).

The ability of a tumor to continue to survive and proliferate in an 
otherwise inhospitable environment requires additional molecular 
and cellular changes. Studies of tumor maintenance are typically 
focused on defining the key signals required for these processes and 
form the basis for targeted chemotherapy. Studies in GEM models 

Opportunities provided by employing GEM cancer models

	
	
	

	
	

	

Provide initial “filter” to identify molecular targets that, when inhibited, kill cancer cells
Investigate mechanisms underlying responsiveness and resistance to conventional cancer therapies
Define discrete steps of tumorigenesis
Determine the role of the microenvironment in tumor formation and progression
Identify surrogate markers of tumor growth and response to therapy
Define epigenetic and environmental influences on tumorigenesis

848	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006

review

and in human patients have implied	that molecular changes impor-
tant for cancer formation are also necessary for maintenance. For 
example, studies in which tetracycline-regulatable alleles of onco-
genic RAS and MYC were “shut off” in established tumors resulted 
in dramatic tumor regression (56–58). Furthermore, the emergence 
of imatinib-resistant mutant alleles of BCR-ABL in patients with 
chronic myeloid leukemia (59, 60) argues strongly that the cancer-
initiating mutation remains central to the tumor’s growth advan-
tage. However, other data suggest that cancer cells can escape from 
dependence on the initiating oncogenic lesion under some circum-
stances (61, 62). The exact mechanisms underlying “tumor escape” 
have not been fully elucidated; but they may reflect a change in the 
histologic phenotype of the tumor, loss of expression of the initiat-
ing oncogene, or the acquisition of additional genetic changes (63). 
The ability of some cancers to free themselves from dependence on 
the initiating molecular event likely has implications for the design 
of targeted therapies for recurrent tumors.

Tumors frequently evolve from a benign neoplastic lesion to a 
more malignant cancer. This progression involves the acquisition 
of additional genetic changes, which also serve as targets for che-
motherapeutic drug design. For example, during the progression 
to malignant cancer, some low-grade astrocytomas somatically 
acquire a constitutively active version of the EGFR. This signature 
genetic event formed the basis for the development of targeted 
therapies directed against this mutant EGFR in both mice and 
humans (64, 65). GEM models were important in demonstrating 
that the EGFR mutation is a causative genetic change that acceler-
ates malignant transformation (66, 67).

Tumor microenvironment. GEM cancer models have been powerful 
tools for examining the contribution of the tumor microenviron-
ment to tumor formation. Studies of peripheral and central ner-
vous system tumors in a mouse model of the NF1 familial cancer 
syndrome demonstrated that tumor formation requires that loss 
of Nf1 expression in Schwann cells (neurofibromas) or astrocytes 
(optic glioma) occur in the context of a heterozygous germline Nf1 
mutation (43, 44). These data demonstrate that heterozygous Nf1 
mutant cells in the microenvironment of preneoplastic lesions 
participate in tumorigenesis. Nonmalignant stromal cells also con-
tribute to mammary carcinoma, in which loss of TGF-β receptor 
expression in fibroblasts promotes mammary ductal carcinoma 
growth and invasion by upregulating specific signaling networks 
(68, 69). Last, angiogenesis plays a fundamental role in tumor for-
mation and progression and has formed the biological basis for 
numerous clinical trials using antiangiogenic therapies (70, 71). 
GEM models have been instructive in defining the molecular basis 
for new blood vessel formation by tumors and the impact of angio-
genesis on tumor progression (72, 73).

Radiologic and serum biomarkers. The ability to define individuals 
at high risk of developing cancer and the ability to noninvasively 
monitor disease burden during and after cancer treatment have 
substantial implications for clinical practice. GEM models have 
been employed to identify serum biomarkers for cancer using 
advanced proteomics methods. While these studies are still in their 
early phases of discovery, one serum biomarker has been identified 
for murine prostate cancer that correlated well with tumor weight 
and response to hormone therapy (74). In addition to serum bio-
markers, MRI	has recently been evaluated for its ability to provide 
information regarding therapeutic efficacy in brain tumors. MRI 
of mice bearing brain tumors demonstrated that the tissue diffu-
sion values obtained early after standard chemotherapy correlated 

with tumor response (75). These results prompted an investigation 
of human brain tumors, which showed that tissue diffusion values 
obtained 3 weeks after the initiation of chemotherapy could pre-
dict patient response (76). Similar to serum biomarkers, the ability 
of MRI to define patients with recurrent disease or who do not 
respond to first-line therapy would allow for early intervention 
and the administration of alternative therapies.

Modifier genes. Unlike humans, GEM models can be generated 
on homogeneous genetic backgrounds, which greatly facilitate 
identifying modifier genes that influence the incidence or clini-
cal behavior of specific cancers. Numerous candidate genetic loci 
have been found that influence tumor number and size in mouse 
lung and colon cancer (77–79) as well as tumor type in mice 
harboring identical genetic mutations. For example, the tumor 
spectrum in mice harboring mutations in the p53 and Nf1 genes 
is dictated by the genetic background, which led to the identi-
fication of a locus on mouse chromosome 11 that determined 
susceptibility to astrocytoma (80). Last, genes that function to 
identify DNA polymerase errors during DNA replication (DNA 
mismatch repair genes) have been shown to modify colon cancer 
tumor burden and survival in GEM (81–83).

Performing preclinical studies in mice
Evaluating conventional cancer therapies in human patients. There 
are well-established paradigms for testing new drugs in human 
patients. New agents are typically evaluated in 3 phases. As the 
primary goal of a phase 1 trial is to determine the MTD of a drug, 
these studies typically involve administering a single agent to 
patients with a variety of different tumor types who have failed 
to respond to standard therapies. Phase 2 trials are designed to 
measure response rates in a group of patients with refractory or 
recurrent cancers treated at the MTD. Responses are tradition-
ally reported as “complete” (objective regression of all detectable 
lesions), “partial” (some regression), or “mixed” (regression of 
some lesions with growth of others). Compounds that show sig-
nificant promise in phase 2 studies are advanced to randomized 
phase 3 trials, in which the new drug is compared, either alone or 
in combination with other agents, to the “standard” treatment for 
a specific cancer. In contrast to phase 1 and phase 2 trials, phase 3 
studies include newly diagnosed patients and are frequently per-
formed in the setting of cooperative multi-institutional networks. 
Because phase 2 and phase 3 studies are logistically challenging, 
expensive, and time consuming, pharmaceutical and biotechnol-
ogy companies are understandably most interested in testing 
agents that might be approved to treat patients with common 
cancers. Importantly, phase 1 trials in patients with refractory 
cancers may not accurately mimic response rates in persons with 
de novo disease, and it has been difficult to test drug combina-
tions in phase 1 and phase 2 trials. GEM cancer models offer the 
possibility of overcoming these 2 problems.

Using GEM cancer models to investigate responsiveness and resistance 
to conventional anticancer agents. Relatively few studies of conven-
tional cytotoxic agents have been performed in GEM models. 
This is due, in part, to the fact that many investigators who gen-
erate GEM cancer models lack expertise in performing preclini-
cal studies. Although much less expensive than human clinical 
trials, investigating drugs in mice is challenging due to factors 
that include the need to generate and maintain cohorts of mice 
that spontaneously develop tumors, difficulties in assessing the 
responses of tumors that can only be visualized by small-animal 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006 

849

review

are largely limited to APL; the efficacy of imatinib correlates with 
biochemical inhibition of specific mutant kinases (BCR-ABL, c-
kit, and PDGF); and the presence of activating EGFR mutations 
predicts clinical responsiveness to gefitinib in lung cancer (25, 
87–91). In a recent study, coexpression of a mutant EGFR recep-
tor and an intact PTEN gene correlated with the response of high-
grade malignant astrocytoma to EGFR inhibitors (92). Similarly, 
although RAS and BRAF mutations both encode proteins that 
deregulate MEK/ERK signaling in melanoma, cancer cell lines 
with BRAF mutations are highly sensitive to MEK inhibitors, 
whereas cells with RAS mutations are not (93).

Harnessing GEM cancer models to enhance the development of new 
therapies. Academic researchers, pharmaceutical companies, gov-
ernment agencies, and patient advocacy groups have all expressed 
concern about the apparent “disconnect” between our growing 
understanding of cancer biology and the relatively few instances 
in which these advances have been successfully translated into 
better cancer treatments. The authors recently participated in a 
meeting that examined how mouse models of tumors that develop 
in persons with NF1 and NF2 could be efficiently employed to 
inform human clinical trials	(“Barriers and Solutions in the Use 
of Mouse Models to Develop Therapeutic Strategies for Neuro-
fibromatosis-Associated Tumors,” Banbury Center, Cold Spring 
Harbor Laboratories, November 3–5, 2005). Individuals with NF1 
are predisposed to the development of specific benign and malig-
nant tumors, including cutaneous and plexiform neurofibro-
mas, low-grade astrocytoma, juvenile myelomonocytic leukemia 
(JMML), and malignant peripheral nerve sheath tumor (MPNST), 
while persons with NF2 develop schwannoma, meningioma, and 
ependymoma (94). Because NF1- and NF2-associated tumors are 
relatively uncommon, pharmaceutical and biotechnology compa-
nies are not actively engaged in developing drugs for these specific 
indications. However, the molecular genetics of human NF1 and 
NF2 are understood in detail, and elegant mouse models of most 
NF-associated tumors are available. Many companies are develop-
ing drugs that interfere with components of the RAS signaling 
network, which might prove effective in some NF1-associated 
tumors. Unfortunately, performing clinical trials in NF1 patients 
is difficult for a variety of reasons, including the slow and predict-
able growth rates of many of these tumors, the propensity to affect 
children, and relatively small patient numbers. GEM models of 
JMML and MPNST are characterized by rapid growth and relative 
ease of measuring treatment responses (45, 46, 95, 96). These in 
vivo models, and tumor cells from these mice, could be used to 
rapidly screen candidate drugs for a beneficial therapeutic index, 
and promising agents might be investigated further by perform-
ing detailed PK/PD studies. By contrast, evaluating therapeutics in 
the existing neurofibroma and optic glioma GEM models is more 
difficult due to their relatively slow growth rates and requirement 
for small-animal imaging (43, 44). These models might be more 
useful for studies of preventive agents or for “front-line” preclini-
cal studies of compounds that target cells in the tumor microen-
vironment. The overall goal of this type of strategy (Figure 1) is to 
optimally employ the available GEM tumor models as “filters” to 
select agents for human trials that have the greatest likelihood of 
succeeding in the clinic. In this proposed strategy, new drugs could 
be rapidly screened for efficacy, target validation, and potential 
“off-target” effects in GEM models that lend themselves well to 
rapid throughput (e.g., Nf1 MPNST and leukemia GEM models). 
Drugs active in these paradigms would be further studied to define 

Figure 1
Use of GEM tumor models as “filters” to select agents for human clini-
cal trials. One strategy has been proposed for use in the Nf1 GEM 
models community, which involves the evaluation of new therapies in 
multiple mouse strains. New drugs would be rapidly screened using 
MPNST and leukemia GEM models for efficacy (therapeutic index), 
target validation, and potential “off-target” effects. These GEM models 
would be utilized for initial evaluation, based on the rapid growth of the 
tumors and the relative ease of measuring tumor growth. Drugs that 
exhibit activity in these models would be further analyzed in detailed 
PK/PD studies in other tumor models, such as orthotopic tumor explant 
models and transgenic mice harboring specific deregulated cancer-
associated molecules or pathways. Optic glioma and neurofibroma 
(plexiform neurofibroma) GEM models may be better suited for che-
moprevention studies as well as investigations of drugs that target 
specific cells in the tumor microenvironment (e.g., microglia and mast 
cells). Collectively, the combined use of each of the available robust 
preclinical GEM models would afford researchers the opportunity to 
comprehensively evaluate drugs prior to considering human clinical 
trials. Adapted with permission from a summary presentation by Susan 
Blaney, Cold Spring Harbor Laboratories, Banbury Center conference 
on “Barriers and Solutions in the Use of Mouse Models to Develop 
Therapeutic Strategies for Neurofibromatosis-Associated Tumors,” 
November 3–5, 2005.

imaging (e.g., MRI), and the limited availability of laboratory sup-
port to measure PK/PD endpoints. Similarly, it is important to 
understand why some human tumors are inherently insensitive 
to chemotherapeutic agents, while other cancers initially respond 
but later become resistant when patients relapse. Pioneering stud-
ies in an Eµ-Myc B cell lymphoma model have shown that some of 
the genetic lesions that contribute to cancer, such as Tp53 inacti-
vation or deregulated Bcl2 expression, also modulate resistance to 
chemotherapeutic agents (84, 85).

Evaluating molecularly targeted inhibitors in humans and in GEM 
models. Some traditional strategies for evaluating new cancer ther-
apeutics are being reconsidered as more specific agents are devel-
oped (86). Target inhibition, rather than overt clinical toxicity 
(e.g., MTD), may represent a better endpoint for phase 1 testing of 
drugs with a well-defined biochemical target. Additionally, there 
are now many examples that underscore the importance of prese-
lecting patients with specific molecular abnormalities for target-
ed therapies trials. In this regard, the beneficial effects of ATRA 

850	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006

review

their bioavailability and pharmacokinetics in other GEM model 
systems (e.g., orthotopic transplant or transgenic mouse models). 
Secondary evaluation of candidate drugs would then entail the 
use of additional GEM strains (e.g., Nf1 optic glioma and neurofi-
broma GEM models) in which tumor microenvironment plays an 
important role in cancer formation. These latter GEM models are 
uniquely suited for chemoprevention studies as well as for examin-
ing drugs directed against specific cell types in the tumor microen-
vironment (e.g., immune system cells, endothelial cells). The com-
bined use of multiple complementary preclinical model systems 
provides an excellent opportunity to comprehensively evaluate 
lead compounds under conditions that closely approximate the 
human condition prior to the initiation of human clinical trials.

Given the pressing need to develop new cancer therapies, it is 
important to establish preclinical testing paradigms that provide 
the greatest opportunities to optimally translate results obtained 
in GEM cancer models into the clinic. We recommend that inves-
tigators take advantage of the multiple complementary GEM can-

cer models now available to evaluate new agents in order to best 
inform subsequent human clinical trials.

Acknowledgments
We apologize to investigators whose work we were not able to 
discuss in this focused review. Our research in this area is sup-
ported by grants from the US Army, American Cancer Society, 
James S. McDonnell Foundation, and NIH. The impetus for writ-
ing this review was the Children’s Tumor Foundation–sponsored 
meeting “Barriers and Solutions in the Use of Mouse Models to 
Develop Therapeutic Strategies for Neurofibromatosis-Associated 
Tumors,” held at the Banbury Center, Cold Spring Harbor Labora-
tories, November 3–5, 2005.

Address correspondence to: David H. Gutmann, Department of 
Neurology, Washington University School of Medicine, Box 8111,  
660 S. Euclid Avenue, St. Louis, Missouri 63110, USA. Phone: (314) 
362-7379; Fax: (314) 362-2388; E-mail: gutmannd@neuro.wustl.edu.

  1. Lubet, R.A., Zhang, Z., Wang, Y., and You, M. 2004. 
Chemoprevention of lung cancer in transgenic 
mice. Chest. 125:144S–147S.

  2. Serano, R.D., Pegram, C.N., and Bigner, D.D. 1980. 
Tumorigenic cell culture lines from a spontaneous 
VM/Dk murine astrocytoma (SMA). Acta Neuro-
pathol. (Berl.). 51:53–64.

  3. Pattengale, P.K., and Frith, C.H. 1983. Immuno-
morphologic classification of spontaneous lym-
phoid cell neoplasms occurring in female BALB/c 
mice. J. Natl. Cancer Inst. 70:169–179.

  4. Huebner, R.J., et al. 1976. Prevention of spontane-
ous leukemia in AKR mice by type-specific immu-
nosuppression of endogenous ecotropic virogenes. 
Proc. Natl. Acad. Sci. U. S. A. 73:4633–4635.

  5. Zook, B.C., and Simmens, S.J. 2005. Neurogenic 
tumors in rats induced by ethylnitrosourea. Exp. 
Toxicol. Pathol. 57:7–14.

  6. Di Bisceglie, A.M., Osmack, P., and Brunt, E.M. 
2005. Chemoprevention of hepatocellular carcino-
ma: use of tamoxifen in an animal model of hepa-
tocarcinogenesis. J. Lab. Clin. Med. 145:134–138.

  7. Thompson, H.J., and Singh, M. 2000. Rat models 
of premalignant breast disease. J. Mammary Gland 
Biol. Neoplasia. 5:409–420.

  8. Nagao, M., Ushijima, T., Toyota, M., Inoue, R., and 
Sugimura, T. 1997. Genetic changes induced by 
heterocyclic amines. Mutat. Res. 376:161–167.

  9. Sugiyama, T., Osaka, M., Koami, K., Maeda, S., and 
Ueda, N. 2002. 7,12-DMBA-induced rat leukemia: 
a review with insights into future research. Leuk. 
Res. 26:1053–1068.

  10. Pritchard, D.M., and Przemeck, S.M. 2004. Review 
article: how useful are the rodent animal models of 
gastric adenocarcinoma? Aliment. Pharmacol. Ther. 
19:841–859.

  11. Meuwissen, R., and Berns, A. 2005. Mouse models 

for human lung cancer. Genes Dev. 19:643–664.

  12. Jamerson,  M.H.,  Johnson,  M.D.,  and  Dickson, 
R.B. 2004. Of mice and Myc: c-Myc and mammary 
tumorigenesis. J. Mammary Gland Biol. Neoplasia. 
9:27–37.

  13. Abate-Shen,  C.,  and  Shen,  M.M.  2002.  Mouse 
models of prostate carcinogenesis. Trends Genet. 
18:S1–S5.

  14. Giannini, C., et al. 2005. Patient tumor EGFR and 
PDGFRA gene amplifications retained in an inva-
sive intracranial xenograft model of glioblastoma 
multiforme. Neuro-oncology. 7:164–176.

  15. Pieper, R.O. 2003. Defined human cellular systems 
in the study of glioma development. Front. Biosci.  
8:s19–s27.

  16. Singh, S.K., et al. 2004. Identification of human 
brain tumour initiating cells. Nature. 432:396–401.

  17. Frijhoff, A.F., Conti, C.J., and Senderowicz, A.M. 
2004. Advances in molecular carcinogenesis: cur-
rent and future use of mouse models to screen and 
validate molecularly targeted anticancer drugs. 
Mol. Carcinog. 39:183–194.

  18. Oost, T.K., et al. 2004. Discovery of potent antago-
nists of the antiapoptotic protein XIAP for the 
treatment of cancer. J. Med. Chem. 47:4417–4426.

  19. National Cancer Institute. MMHCC cancer models 

database. http://cancermodels.nci.nih.gov.

  20. Jackson, E.L., et al. 2001. Analysis of lung tumor ini-
tiation and progression using conditional expres-
sion of oncogenic K-ras. Genes Dev. 15:3243–3248.

  21. Fisher, G.H., et al. 1999. Development of a flexible 
and specific gene delivery system for production of 
murine tumor models. Oncogene. 18:5253–5260.

  22. Tallman, M.S. 1998. Therapy of acute promyelo-
cytic leukemia: all-trans retinoic acid and beyond. 
Leukemia. 12(Suppl. 1):S37–S40.

  23. Licht,  J.D.,  et  al.  1995.  Clinical  and  molecular 
characterization of a rare syndrome of acute pro-
myelocytic leukemia associated with translocation 
(11;17). Blood. 85:1083–1094.

  24. He, L.Z., et al. 1998. Distinct interactions of PML-
RARalpha and PLZF-RARalpha with co-repressors 
determine differential responses to RA in APL. Nat. 
Genet. 18:126–135.

  25. Rego, E.M., He, L.Z., Warrell, R.P., Jr., Wang, Z.G., 
and Pandolfi, P.P. 2000. Retinoic acid (RA) and 
As2O3 treatment in transgenic models of acute 
promyelocytic leukemia (APL) unravel the distinct 
nature of the leukemogenic process induced by the 
PML-RARalpha and PLZF-RARalpha oncoproteins.  
Proc. Natl. Acad. Sci. U. S. A. 97:10173–10178.

  26. Look, A.T. 1998. Arsenic and apoptosis in the treat-
ment of acute promyelocytic leukemia. J. Natl. Cancer  
Inst. 90:86–88.

  27. Zhu, Y., et al. 2005. Inactivation of NF1 in CNS causes 
increased glial progenitor proliferation and optic 
glioma formation. Development. 132:5577–5588.

  28. Shannon, K.M., Le Beau, M.M., Largaespada, D.A., 
and Killeen, N. 2001. Modeling myeloid leukemia 
tumor suppressor gene inactivation in the mouse. 
Semin. Cancer Biol. 11:191–200.

  29. Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaugh-
lin, M.E., and Jacks, T. 2000. Nf1;Trp53 mutant 
mice develop glioblastoma with evidence of strain-
specific effects. Nat. Genet. 26:109–113.

  30. Kalamarides, M., et al. 2002. Nf2 gene inactivation 
in arachnoidal cells is rate-limiting for menin-
gioma  development  in  the  mouse.  Genes  Dev. 
16:1060–1065.

  31. Giovannini, M., et al. 2000. Conditional biallelic Nf2 
mutation in the mouse promotes manifestations  

of human neurofibromatosis type 2. Genes Dev. 
14:1617–1630.

  32. Moser, A.R., et al. 1993. ApcMin, a mutation in the 
murine Apc gene, predisposes to mammary carci-
nomas and focal alveolar hyperplasias. Proc. Natl. 
Acad. Sci. U. S. A. 90:8977–8981.

  33. Luongo, C., Moser, A.R., Gledhill, S., and Dove, 
W.F. 1994. Loss of Apc+ in intestinal adenomas 
from Min mice. Cancer Res. 54:5947–5952.

  34. Johnson, L., et al. 2001. Somatic activation of the 
K-ras oncogene causes early onset lung cancer in 
mice. Nature. 410:1111–1116.

  35. Chan, I.T., et al. 2004. Conditional expression of 
oncogenic K-ras from its endogenous promoter 
induces a myeloproliferative disease. J. Clin. Invest. 
113:528–538. doi:10.1172/JCI200420476.

  36. Tuveson, D.A., et al. 2004. Endogenous oncogenic 
K-ras(G12D) stimulates proliferation and wide-
spread  neoplastic  and  developmental  defects.  
Cancer Cell. 5:375–387.

  37. Le Beau, M.M., Bitts, S., Davis, E.M., and Kogan, 
S.C. 2002. Recurring chromosomal abnormalities 
in leukemia in PML-RARA transgenic mice paral-
lel human acute promyelocytic leukemia. Blood. 
99:2985–2991.

  38. Zhu, J., et al. 2005. A sumoylation site in PML/
RARA is essential for leukemic transformation. 
Cancer Cell. 7:143–153.

  39. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, 
J., and Berns, A. 2000. Induction of medulloblasto-
mas in p53-null mutant mice by somatic inactiva-
tion of Rb in the external granular layer cells of the 
cerebellum. Genes Dev. 14:994–1004.

  40. Wijnhoven, S.W., et al. 2005. Mice expressing a 
mammary gland-specific R270H mutation in the 
p53 tumor suppressor gene mimic human breast 
cancer development. Cancer Res. 65:8166–8173.

  41. Olive, K.P., et al. 2004. Mutant p53 gain of function 
in two mouse models of Li-Fraumeni syndrome. 
Cell. 119:847–860.

  42. Zhu, Y., et al. 2005. Early inactivation of p53 tumor 
suppressor gene cooperating with NF1 loss induces 
malignant astrocytoma. Cancer Cell. 8:119–130.

  43. Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K., and 
Parada, L.F. 2002. Neurofibromas in NF1: Schwann 
cell origin and role of tumor environment. Science. 
296:920–922.

  44. Bajenaru, M.L., et al. 2003. Optic nerve glioma in 
mice requires astrocyte Nf1 gene inactivation and 
Nf1 brain heterozygosity. Cancer Res. 63:8573–8577.
  45. Cichowski, K., et al. 1999. Mouse models of tumor 
development in neurofibromatosis type 1. Science. 
286:2172–2176.

  46. Vogel, K.S., et al. 1999. Mouse tumor model for 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006 

851

review

neurofibromatosis type 1. Science. 286:2176–2179.
  47. Kohl, N.E., et al. 1995. Inhibition of farnesyltransfer-
ase induces regression of mammary and salivary car-
cinomas in ras transgenic mice. Nat. Med. 1:792–797.
  48. Lobell, R.B., et al. 2001. Evaluation of farnesyl:
protein  transferase  and  geranylgeranyl:protein 
transferase inhibitor combinations in preclinical 
models. Cancer Res. 61:8758–8768.

  49. Omer, C.A., et al. 2000. Mouse mammary tumor 
virus-Ki-rasB transgenic mice develop mammary 
carcinomas  that  can  be  growth-inhibited  by  a 
farnesyl:protein transferase inhibitor. Cancer Res. 
60:2680–2688.

  50. Mahgoub, N., et al. 1999. In vitro and in vivo effects 
of a farnesyltransferase inhibitor on Nf1-deficient 
hematopoietic cells. Blood. 94:2469–2476.

  51. Hecht, S.S. 2005. Carcinogenicity studies of inhaled 
cigarette smoke in laboratory animals: old and new. 
Carcinogenesis. 26:1488–1492.

  52. Shen, Q., and Brown, P.H. 2005. Transgenic mouse 
models for the prevention of breast cancer. Mutat. 
Res. 576:93–110.

  53. Kavanaugh, C., and Green, J.E. 2003. The use of 
genetically altered mice for breast cancer preven-
tion studies. J. Nutr. 133:2404S–2409S.

  54. Altomare, D.A., et al. 2005. A mouse model reca-
pitulating molecular features of human mesothe-
lioma. Cancer Res. 65:8090–8095.

  55. Fleury-Feith, J., et al. 2003. Hemizygosity of Nf2 
is  associated  with  increased  susceptibility  to 
asbestos-induced peritoneal tumours. Oncogene. 
22:3799–3805.

  56. Chin, L., et al. 1999. Essential role for oncogenic 
Ras in tumour maintenance. Nature. 400:468–472.
  57. Felsher, D.W., and Bishop, J.M. 1999. Reversible 
tumorigenesis by MYC in hematopoietic lineages. 
Mol. Cell. 4:199–207.

  58. Jain, M., et al. 2002. Sustained loss of a neoplastic 
phenotype by brief inactivation of MYC. Science. 
297:102–104.

  59. Gorre, M.E., et al. 2001. Clinical resistance to STI-
571 cancer therapy caused by BCR-ABL gene muta-
tion or amplification. Science. 293:876–880.

  60. Shah, N.P., et al. 2002. Multiple BCR-ABL kinase 
domain mutations confer polyclonal resistance to 
the tyrosine kinase inhibitor imatinib (STI571) in 
chronic phase and blast crisis chronic myeloid leu-
kemia. Cancer Cell. 2:117–125.

  61. Moody, S.E., et al. 2002. Conditional activation 
of Neu in the mammary epithelium of transgenic 
mice results in reversible pulmonary metastasis. 
Cancer Cell. 2:451–461.

  62. Gunther, E.J., et al. 2003. Impact of p53 loss on 
reversal and recurrence of conditional Wnt-induced 
tumorigenesis. Genes Dev. 17:488–501.

  63. Giuriato, S., and Felsher, D.W. 2003. How cancers 
escape their oncogene habit. Cell Cycle. 2:329–332.

  64. Krishnan, S., Rao, R.D., James, C.D., and Sarkaria, 
J.N. 2003. Combination of epidermal growth factor 
receptor targeted therapy with radiation therapy 
for malignant gliomas. Front. Biosci. 8:e1–e13.

  65. Kuan, C.T., Wikstrand, C.J., and Bigner, D.D. 2000. 
EGFRvIII as a promising target for antibody-based 
brain tumor therapy. Brain Tumor Pathol. 17:71–78.
  66. Holland, E.C., Hively, W.P., DePinho, R.A., and Var-
mus, H.E. 1998. A constitutively active epidermal 
growth factor receptor cooperates with disruption 
of G1 cell-cycle arrest pathways to induce glioma-
like lesions in mice. Genes Dev. 12:3675–3685.

  67. Ding, H., et al. 2003. Oligodendrogliomas result from 
the expression of an activated mutant epidermal 
growth factor receptor in a RAS transgenic mouse 
astrocytoma model. Cancer Res. 63:1106–1113.

  68. Cheng, N., et al. 2005. Loss of TGF-beta type II 
receptor in fibroblasts promotes mammary carci-
noma growth and invasion through upregulation 
of TGF-alpha-, MSP- and HGF-mediated signaling 
networks. Oncogene. 24:5053–5068.

  69. Bhowmick, N.A., et al. 2004. TGF-beta signaling in 
fibroblasts modulates the oncogenic potential of 
adjacent epithelia. Science. 303:848–851.

  70. Folkman, J. 2003. Fundamental concepts of the 

angiogenic process. Curr. Mol. Med. 3:643–651.

  71. Ellis, L.M. 2004. Preclinical data targeting vascular 
endothelial growth factor in colorectal cancer. Clin. 
Colorectal Cancer. 4(Suppl. 2):S55–S61.

  72. Korc, M. 2003. Pathways for aberrant angiogenesis 

in pancreatic cancer. Mol. Cancer. 2:8.

  73. Hoffman, R. 2002. Green fluorescent protein imag-
ing of tumour growth, metastasis, and angiogen-
esis in mouse models. Lancet Oncol. 3:546–556.

  74. Huizen, I.V., et al. 2005. Establishment of a serum 
tumor marker for preclinical trials of mouse pros-
tate cancer models. Clin. Cancer Res. 11:7911–7919.
  75. Chenevert, T.L., et al. 2000. Diffusion magnetic 
resonance imaging: an early surrogate marker of 
therapeutic efficacy in brain tumors. J. Natl. Cancer 
Inst. 92:2029–2036.

  76. Moffat, B.A., et al. 2005. Functional diffusion map: 
a noninvasive MRI biomarker for early stratifica-
tion of clinical brain tumor response. Proc. Natl. 
Acad. Sci. U. S. A. 102:5524–5529.

  77. Malkinson, A.M. 2001. Primary lung tumors in 
mice as an aid for understanding, preventing, and 
treating human adenocarcinoma of the lung. Lung 
Cancer. 32:265–279.

  78. Mullerova, J., and Hozak, P. 2004. Use of recombi-
nant congenic strains in mapping disease-modify-
ing genes. News Physiol. Sci. 19:105–109.

  79. Haines, J., et al. 2005. Genetic basis of variation in 
adenoma multiplicity in ApcMin/+ Mom1S mice. 
Proc. Natl. Acad. Sci. U. S. A. 102:2868–2873.

  80. Reilly, K.M., et al. 2004. Susceptibility to astrocyto-
ma in mice mutant for Nf1 and Trp53 is linked to 

chromosome 11 and subject to epigenetic effects. 
Proc. Natl. Acad. Sci. U. S. A. 101:13008–13013.

  81. Kuraguchi, M., et al. 2000. Tumor-associated Apc 
mutations in Mlh1–/– Apc1638N mice reveal a 
mutational signature of Mlh1 deficiency. Oncogene. 
19:5755–5763.

  82. Edelmann, W., et al. 1999. Tumorigenesis in Mlh1 
and  Mlh1/Apc1638N  mutant  mice.  Cancer Res. 
59:1301–1307.

  83. Edelmann,  W.,  et  al.  1999.  Mammalian  MutS 
homologue 5 is required for chromosome pairing 
in meiosis. Nat. Genet. 21:123–127.

  84. Hemann,  M.T.,  et  al.  2005.  Evasion  of  the  p53 
tumour surveillance network by tumour-derived 
MYC mutants. Nature. 436:807–811.

  85. Johnstone, R.W., Ruefli, A.A., and Lowe, S.W. 2002. 
Apoptosis: a link between cancer genetics and che-
motherapy. Cell. 108:153–164.

  86. Druker, B.J. 2002. Perspectives on the development 
of a molecularly targeted agent. Cancer Cell. 1:31–36.
  87. He, L.Z., Merghoub, T., and Pandolfi, P.P. 1999. 
In vivo analysis of the molecular pathogenesis of 
acute promyelocytic leukemia in the mouse and its 
therapeutic implications. Oncogene. 18:5278–5292.
  88. Hughes,  T.,  and  Branford,  S.  2006.  Molecular 
monitoring of BCR-ABL as a guide to clinical man-
agement in chronic myeloid leukaemia. Blood Rev. 
20:29–41.

  89. Carter, T.A., et al. 2005. Inhibition of drug-resistant 
mutants of ABL, KIT, and EGF receptor kinases. 
Proc. Natl. Acad. Sci. U. S. A. 102:11011–11016.

  90. Apperley, J.F., et al. 2002. Response to imatinib 
mesylate in patients with chronic myeloprolifera-
tive diseases with rearrangements of the platelet-
derived growth factor receptor beta. N. Engl. J. Med. 
347:481–487.

  91. Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., 
and Cherrington, J.M. 2003. SU11248 inhibits KIT 
and platelet-derived growth factor receptor beta in 
preclinical models of human small cell lung cancer. 
Mol. Cancer Ther. 2:471–478.

  92. Mellinghoff, I.K., et al. 2005. Molecular determi-
nants of the response of glioblastomas to EGFR 
kinase inhibitors. N. Engl. J. Med. 353:2012–2024.

  93. Solit, D.B., et al. 2006. BRAF mutation predicts sen-

sitivity to MEK inhibition. Nature. 439:358–362.

  94. Gutmann, D.H., et al. 1997. The diagnostic evalu-
ation and multidisciplinary management of neu-
rofibromatosis 1 and neurofibromatosis 2. JAMA. 
278:51–57.

  95. Bollag, G., et al. 1996. Loss of NF1 results in acti-
vation of the Ras signaling pathway and leads to 
aberrant growth in haematopoietic cells. Nat. Genet. 
12:144–148.

  96. Le, D.T., et al. 2004. Somatic inactivation of Nf1 in 
hematopoietic cells results in a progressive myelo-
proliferative disorder. Blood. 103:4243–4250.

852	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006

